Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt
Links:
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Ar…
https://acrabstracts.org/abstract/bimekizumab-treatment-in-biologic-dmard-naive…
14-11-2022